Results 181 to 190 of about 275,402 (290)

Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma. [PDF]

Oncoimmunology
Falchi L, Hutchings M, Tybor D, Yu J, Alshreef A, Wang A, Sail K, Ding Z, Mutebi A, Patah P, Kishore N, Rana A, Favaro E, Linton K.   +13 more
europepmc   +1 more source

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

American Journal of Hematology, Volume 101, Issue 9, Page 2177-2189, September 2026.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez, Mariana Bastos‐Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam J. Olszewski, Seema Naik, Nilanjan Ghosh, Song Pham, Michael C. Wei, Connie Batlevi, Iris To, Wahib Ead, Sneha Makadia, Elicia Penuel, Jing Jing, Lihua E. Budde   +17 more
wiley   +1 more source

Paraneoplastic pemphigus associated with follicular lymphoma and myasthenia gravis: Efficacy of a lenalidomide-rituximab-corticosteroid regimen. [PDF]

JAAD Case Rep
Shen Y, Wang Q, Xu C, Zhu W, Zhu H, Pan M, Wang J.   +6 more
europepmc   +1 more source

The Molecular and Immunological Landscape in Nasopharyngeal Carcinoma (NPC) Differs by Somatostatin Receptor 2 (SSTR2) Expression

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Somatostatin receptor 2 is expressed in nasopharyngeal carcinoma (NPC). We report genomic and transcriptomic analysis results of 163 NPC cases, demonstrating that somatostatin receptor 2 (SSTR2) gene expression in EBV‐positive and in EBV‐negative NPC correlated with genomic alterations and an inflamed microenvironment.
Dara Bracken‐Clarke, Elisabetta Xue, Harris Krause, Tolulope Adeyelu, Mark G. Evans, Dilara Akbulut, Martha Quezado, Nishant Gandhi, Alex Farrell, Heloisa P. Soares, Emil Lou, Minh Phan, Rusha Patel, Ari M. Vanderwalde, Andrew Elliott, Conor E. Steuer, Nabil F. Saba, Daniel J. Lubin, Nyall R. London Jr, James L. Gulley, Charalampos S. Floudas   +20 more
wiley   +1 more source

Unmasking a Composite Lymphoma: Follicular Lymphoma Emerging After Bispecific Antibody Treatment of Marginal Zone Lymphoma. [PDF]

EJHaem
Orosco-Ttamina AL, Zhou J, Biondo J, Hossain F, Viswanatha D, Greipp PT, Lewis N, Munoz J.   +7 more
europepmc   +1 more source

Target‐Specific Dermatological Adverse Event Reporting With T‐Cell–Engaging Bispecific Antibodies: A Pharmacovigilance Analysis of FAERS and Canada Vigilance, 2016–2026

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background T‐cell–engaging bispecific antibodies are increasingly utilised in haematological malignancies and are beginning to be adopted in solid‐tumour treatment protocols. Cytokine release syndrome and neurotoxicity are well recognised, but target‐specific dermatological adverse event reporting patterns remain poorly defined.
Saikat Mandal, Manideepa Maji, Arkadeep Dhali   +2 more
wiley   +1 more source

Spontaneous Metabolic Regression in High-Burden Follicular Lymphoma: A Case Report. [PDF]

Case Rep Hematol
Bronstein Y, Vitkon R, Hayman L, Perry C.   +3 more
europepmc   +1 more source

Diagnostic potential of B‐cell translocation gene 2 in IgA nephropathy: Insights from molecular mechanisms

Journal of Cell Communication and Signaling, Volume 20, Issue 3, September 2026.
Diagnostic value of BTG2 and its immunoregulatory mechanism in IgAN. This study reveals that BTG2 improves immune microenvironment dysregulation, attenuates inflammation, and reduces fibrosis by promoting the expansion of T follicular helper cells, inducing macrophage polarization toward an M2 anti‐inflammatory phenotype, and inhibiting the TGF‐β1 ...
Min Kou, Mo Dan, Juan Cheng, Sheng Ge, Ruimin Ren   +4 more
wiley   +1 more source

Mosunetuzumab for relapsed follicular lymphoma presenting with chylothorax: A case report and literature review. [PDF]

J Clin Exp Hematop
Naganuma K, Hirata K, Arai Y, Tezuka S, Matsunaga T, Kawada T, Sakata N, Takahashi Y, Yamashita T, Momose S, Higashi M, Tabayashi T.   +11 more
europepmc   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 614-638, September 2026.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source